INTEGER HOLDINGS CORPORATION (ITGR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-07-03..
- Stock-based compensation / revenue · 12 months: Value 1.23%; Formula and calculation Share-based compensation / revenue. Period ending 2026-07-03..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-07-03; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-07-03. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.23% | Share-based compensation / revenue. Period ending 2026-07-03. $22.73M ÷ $1.84B × 100 ≈ 1.23% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 1.84B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 22.73M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 178.77M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-03 | (m) | $1.84B | $22.73M | $178.77M | (m) | (m) | 1.23% | (m) | (m) |
| 2026-04-03 | (m) | $1.86B | $23.01M | $203.58M | (m) | (m) | 1.24% | (m) | (m) |
| 2025-12-31 | (m) | $1.85B | $23.22M | $221.26M | (m) | (m) | 1.25% | (m) | (m) |
| 2025-09-26 | (m) | $1.83B | $23.50M | $222.36M | (m) | (m) | 1.28% | (m) | (m) |
| 2025-06-27 | (m) | $1.79B | $24.69M | $223.93M | (m) | (m) | 1.38% | (m) | (m) |
| 2025-03-28 | (m) | $1.75B | $24.80M | $219.09M | (m) | (m) | 1.42% | (m) | (m) |
| 2024-12-31 | (m) | $1.72B | $24.77M | $208.24M | (m) | (m) | 1.44% | (m) | (m) |
| 2024-09-27 | (m) | $1.71B | $24.91M | $198.75M | (m) | (m) | 1.45% | (m) | (m) |
| 2024-06-28 | (m) | $1.67B | $24.29M | $186.05M | (m) | (m) | 1.46% | (m) | (m) |
| 2024-03-29 | (m) | $1.63B | $24.03M | $172.44M | $50.79M | (m) | 1.47% | 3.40× | Reported |
| 2023-12-31 | (m) | $1.60B | $23.28M | $167.33M | $53.37M | (m) | 1.46% | 3.14× | Reported |
| 2023-09-29 | (m) | $1.56B | $22.15M | $160.68M | $54.90M | (m) | 1.42% | 2.93× | Reported |
| 2023-06-30 | (m) | $1.49B | $21.68M | $141.87M | $53.60M | (m) | 1.45% | 2.65× | Reported |
| 2023-03-31 | (m) | $1.44B | $22.13M | $133.00M | $49.92M | (m) | 1.53% | 2.66× | Reported |
| 2022-12-31 | (m) | $1.38B | $21.02M | $121.33M | $38.63M | (m) | 1.53% | 3.14× | Reported |
| 2022-09-30 | (m) | $1.32B | $19.92M | $113.13M | $29.93M | (m) | 1.51% | 3.78× | Reported |
| 2022-07-01 | (m) | $1.28B | $18.18M | $116.96M | $29.30M | (m) | 1.42% | 3.99× | Reported |
| 2022-04-01 | (m) | $1.24B | $16.48M | $123.60M | $29.06M | (m) | 1.33% | 4.25× | Reported |
| 2021-12-31 | (m) | $1.22B | $16.18M | $135.71M | $31.63M | (m) | 1.33% | 4.29× | Reported |
| 2021-10-01 | (m) | $1.18B | $15.17M | $134.64M | $35.34M | (m) | 1.29% | 3.81× | Reported |
| 2021-07-02 | (m) | $1.11B | $14.87M | $141.31M | $34.65M | (m) | 1.34% | 4.08× | Reported |
| 2021-04-02 | (m) | (m) | $12.13M | $111.14M | $36.39M | (m) | (m) | 3.05× | Reported |
| 2020-12-31 | (m) | $1.07B | $9.16M | $120.61M | $38.22M | (m) | 0.85% | 3.16× | Reported |
| 2020-10-02 | (m) | $1.13B | $8.63M | $115.67M | $41.77M | (m) | 0.76% | 2.77× | Reported |
| 2020-07-03 | (m) | $1.20B | $7.10M | $122.39M | $44.74M | (m) | 0.59% | 2.74× | Reported |
| 2020-04-03 | (m) | $1.27B | $8.32M | $162.54M | $49.08M | (m) | 0.65% | 3.31× | Reported |
| 2019-12-31 | (m) | $1.26B | $9.29M | $157.63M | $52.55M | (m) | 0.74% | 3.00× | Reported |
| 2019-09-27 | (m) | $1.24B | $9.68M | $174.68M | $53.73M | (m) | 0.78% | 3.25× | Reported |
| 2019-06-28 | (m) | $1.24B | $9.80M | $169.66M | $95.92M | (m) | 0.79% | 1.77× | Reported |
| 2019-03-29 | (m) | $1.24B | $9.96M | $164.68M | $97.55M | (m) | 0.81% | 1.69× | Reported |
| 2018-12-28 | (m) | $1.22B | $10.47M | $155.56M | $99.31M | (m) | 0.86% | 1.57× | Reported |
| 2018-09-28 | (m) | $1.54B | $12.47M | $159.51M | $142.58M | (m) | 0.81% | 1.12× | Reported |
| 2018-06-29 | (m) | $1.52B | $12.84M | $153.88M | $103.86M | (m) | 0.84% | 1.48× | Reported |
| 2018-03-30 | (m) | $1.50B | $13.23M | $147.61M | $104.01M | (m) | 0.88% | 1.42× | Reported |
| 2017-12-29 | (m) | $1.46B | $14.68M | $139.44M | $106.46M | (m) | 1.00% | 1.31× | Reported |
| 2017-09-29 | (m) | $1.43B | $11.12M | $135.92M | $108.90M | (m) | 0.78% | 1.25× | Reported |
| 2017-06-30 | (m) | $1.41B | $11.40M | $134.15M | $110.28M | (m) | 0.81% | 1.22× | Reported |
| 2017-03-31 | (m) | $1.40B | $10.24M | $123.68M | $112.55M | (m) | 0.73% | 1.10× | Reported |
| 2016-12-30 | (m) | $1.39B | $8.41M | $108.27M | $111.27M | (m) | 0.61% | 0.97× | Reported |
| 2016-09-30 | (m) | $1.34B | $7.51M | $66.79M | $108.76M | (m) | 0.56% | 0.61× | Reported |
| 2016-07-01 | (m) | $1.14B | $8.37M | $31.13M | $86.71M | (m) | 0.73% | 0.36× | Reported |
| 2016-04-01 | (m) | $971.33M | $9.96M | $14.89M | $60.01M | (m) | 1.03% | 0.25× | Reported |
| 2016-01-01 | (m) | $800.41M | $9.38M | $13.15M | $33.51M | (m) | 1.17% | 0.39× | Reported |
| 2015-10-02 | (m) | $652.57M | $11.70M | $41.03M | $9.20M | (m) | 1.79% | 4.46× | Reported |
| 2015-07-03 | (m) | $677.63M | $12.43M | $56.01M | $4.42M | (m) | 1.83% | 12.67× | Reported |
| 2015-04-03 | (m) | $674.83M | $12.26M | $62.52M | $4.29M | (m) | 1.82% | 14.58× | Reported |
| 2015-01-02 | (m) | $687.79M | $13.19M | $75.65M | $4.25M | (m) | 1.92% | 17.79× | Reported |
| 2014-10-03 | (m) | $694.68M | $13.22M | $71.11M | $4.52M | (m) | 1.90% | 15.73× | Reported |
| 2014-07-04 | (m) | $690.71M | $13.48M | $71.93M | $4.99M | (m) | 1.95% | 14.43× | Reported |
| 2014-04-04 | (m) | $689.96M | $14.85M | $69.52M | $5.36M | (m) | 2.15% | 12.98× | Reported |
| 2014-01-03 | (m) | $663.95M | $14.10M | $61.34M | $11.26M | (m) | 2.12% | 5.45× | Reported |
| 2013-09-27 | (m) | $646.51M | $13.31M | $49.88M | $14.83M | (m) | 2.06% | 3.36× | Reported |
| 2013-06-28 | (m) | $640.12M | $12.72M | $35.01M | $17.71M | (m) | 1.99% | 1.98× | Reported |
| 2013-03-29 | (m) | $635.34M | $11.15M | $28.96M | $20.68M | (m) | 1.75% | 1.40× | Reported |
| 2012-12-28 | (m) | $646.18M | $10.90M | $25.82M | $18.05M | (m) | 1.69% | 1.43× | Reported |
| 2012-09-28 | (m) | $628.74M | $12.29M | $36.96M | $17.30M | (m) | 1.95% | 2.14× | Reported |
| 2012-06-29 | (m) | $599.12M | $11.82M | $47.72M | $17.03M | (m) | 1.97% | 2.80× | Reported |
| 2012-03-30 | (m) | $579.09M | $11.52M | $54.93M | $17.01M | (m) | 1.99% | 3.23× | Reported |
| 2011-12-30 | (m) | $568.82M | $12.08M | $61.70M | $16.93M | (m) | 2.12% | 3.64× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $533.42M | $6.88M | $68.99M | $18.52M | (m) | 1.29% | 3.73× | Reported |
| 2010-10-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-01-01 | (m) | $521.82M | $5.20M | $1.05M | $20.07M | (m) | 1.00% | 0.05× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |